RPI-78M

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRPI-78M
Drug Alias NameReceptinAlpha-cobratoxin-derived peptideAlpha-ImmunokineRPI-78M
ClassificationBiologics
Mechanisms of ActionMuscle-type nicotinic acetylcholine receptor antagonists
TargetsMuscle-type nicotinic acetylcholine receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A